替比夫定治疗HBeAg阳性慢性乙型肝炎的疗效观察  

Efficacy and safety of telbivudine in the treatment of patients with HBeAg positive chronic hepatitis B

作　　者：王金彩[1] 杨道坤[1] 郑继海[1] 刘小红[1] 

机构地区：[1]新乡医学院第一附属医院药剂科,456400

出　　处：《中国现代药物应用》2013年第5期11-12,共2页Chinese Journal of Modern Drug Application

基　　金：2011年度河南省医学科技攻关计划普通项目(项目编号:2011020093)

摘　　要：目的观察替比夫定与拉米夫定治疗HBeAg阳性慢性乙型肝炎患者的临床疗效及安全性。方法将124例慢性乙型肝炎患者随机分为替比夫定组(TBV)62例,拉米夫定组(LVD)23例,疗程均为48周。观察两组治疗12,24,48周时的HBV-DNA阴转率、HbeAg阴转率和ALT复常率及药物的不良反应。结果在治疗12,24和48周时TBV组的HBV-DNA阴转率均显著优于LVD组(P<0.01),HBeAg阴转率和ALT复常率两组比较差异无统计学意义(P>0.05)。两组均未发现明显不良反应。结论替比夫定治疗HBeAg阳性慢性乙型肝炎疗效优于拉米夫定,是抗乙肝病毒治疗的较佳选择。Objective To evaluate the efficacy and safety of Telbivudine （TBV） and Lamivudine （LVD） for patients with HBeAg positive chronic Hepatitis B （CHB）. Methods 124 patients were divided in- to Group Telbivudine（TBV）（62 patients） and Lamivudine （LVD） （64 patients） randomly and were received TBV and LVD for 48 weeks, respectively. HBV-DNA negative-conversion rate, HBeAg negative-conversion rate, Serum ALT normalization rate and adverse reactions of the two agents were monitored at weeks 12, 24 and 48 weeks. Results In the HBV-DNA negative-conversion rate at weeks 12, 24 and 48 weeks, Group TBV is superior to group LAV （P 〈 0.01 ） and there were no significant differences in HBeAg negative-conversion rate and Serum ALT normalization rate between two groups （ P 〉 0. 05 ）. No serious adverse reaction were found in both groups. Conclusion Telbivudine is more effective in inhibiting reproduction of HBV than that of Lamivu- dine and could be used for long-term treatment of the patients with HBeAg positive chronic hepatitis B.

关 键 词：乙型肝炎 乙肝病毒 替比夫定 拉米夫定 疗效 安全性 

分 类 号：R512.62[医药卫生—内科学]